Description: Mekonos is developing a new approach for non-viral cell engineering using a proprietary silicon nano-robotic chip (KAREL) that delivers biomaterial or molecules into potentially, millions of individual cells. This will see a dramatic breakthrough in the genetic engineering treatment of diseases such as cancer. Instead of the more traditional method of using viruses which can cause cancers and are very expensive, our safe, precise and fast silicon based technology, when fully developed will result in an estimated 20-30x cost reduction and a 1000x throughput improvement over competitors.
Mekonos’ mission is to make cell and gene therapy more universally accessible. Toward that goal, we are developing a patent-pending nanorobotic chip technology to deliver any drug molecule into a massive array of single cells in a highly targeted manner for genetic engineering and treatment of diseases such as cancer.
Website: www.mekonos.com
Contact: Steven Banerjee, steven@mekenos.com
Crunchbase: https://www.crunchbase.com/organization/mekonos-2
Program: LAUNCH
Recent Comments